Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 18/20 | 0.72 |
| ▸ | PDE4A | P27815 | 5/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | PDE2A | O00408 | 1/20 | 0.65 |
| ▸ | PDE6D | O43924 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | PDE9A | O76083 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | PDE6A | P16499 | 1/20 | 0.65 |
| ▸ | PDE6G | P18545 | 1/20 | 0.65 |
| ▸ | PDE6B | P35913 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7375297 | 0.84 | PDE5A (0.73) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7164458 | 0.84 | GUSB (0.81) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7404327 | 0.84 | PDE5A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7965710 | 0.83 | PDE5A (0.69) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7408452 | 0.82 | PDE5A (0.67) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7725988 | 0.81 | PDE5A (0.72) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7721585 | 0.81 | PDE5A (0.71) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7718066 | 0.81 | PDE5A (0.71) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7159216 | 0.80 | PDE5A (0.66) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7965712 | 0.80 | PDE5A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PFIZER INC | 2004-05-06 | — | — | US | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | claimed |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | CAMPBELL SIMON FRASER (GB) | 2001-11-22 | — | — | US | claimed |
| EP-0347146-B1 | FUSED PYRIMIDINE DERIVATIVES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-09-01 | — | — | EP | claimed |
| EP-0347146-A2 | Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-12-20 | — | — | EP | claimed |
| JP-2042079-A | — | — | None | — | — | JP | disclosed |
| US-20150250801-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2015-09-10 | — | — | US | disclosed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | disclosed |
| US-20140142077-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | LABORATORIES BESINS INTERNATIONAL, SAS (FR) | 2014-05-22 | — | — | US | disclosed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | disclosed |
| EP-0793486-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016644-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
| EP-0347146-B1 | FUSED PYRIMIDINE DERIVATIVES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-09-01 | — | — | EP | disclosed |
| US-5047404-A | Fused pyrimidine derivatives bronchodilator agents, antiallergens | SMITH KLINE & FRENCH LABORATORIES, LTD. (GB) | 1991-09-10 | — | — | US | disclosed |
| US-5047404-A | Fused pyrimidine derivatives bronchodilator agents, antiallergens | SMITH KLINE & FRENCH LABORATORIES, LTD. (GB) | 1991-09-10 | — | — | US | disclosed |
| JP-H0242079-A | CONDENSED PYRIMIDINE DERIVATIVE AND ITS PREPARATION | SMITH KLINE LTD | 1990-02-13 | — | — | JP | disclosed |
| EP-0347146-A2 | Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE2A | PDE5A 2/4885PDE4A 5/4885PDE4B 7/4885 |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE5A 3481/4885PDE4A 1173/4885PDE4B 1204/4885 |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE2A, PDE3B | PDE5A 4/4885PDE4A 5/4885PDE4B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.